SCHEMBL582252

SCHEMBL582252

CCn1ncc2c(Nc3cccc(OC)c3)c(C=NO)cnc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.49
PDE4A P27815 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
MAPT P10636 3/20 0.41
HTR2C P28335 2/20 0.41
TP53 P04637 1/20 0.41
ALDH1A1 P00352 2/20 0.40
PKM P14618 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
XBP1 P17861 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 1/20 0.39
PIK3CA P42336 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL582993 1.00 PDE4B (0.49) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL582251 1.00 PDE4B (0.49) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL583562 0.89 MAPT (0.47) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL583561 0.89 MAPT (0.47) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL583341 0.87 PDE4B (0.52) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL583022 0.77 PDE4B (0.58) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL583784 0.76 ALDH1A1 (0.49) PDE4BPDE4APDE4CPDE4DMAPT
SCHEMBL583436 0.73 PDE4B (0.48) PDE4BALDH1A1HPGDHTTPDE5A
SCHEMBL582569 0.73 PDE4B (0.48) PDE4BALDH1A1HPGDHTTPDE5A
SCHEMBL582568 0.73 PDE4B (0.48) PDE4BALDH1A1HPGDHTTPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP claimed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US claimed
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US disclosed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP disclosed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE4A, PDE3A PDE4B 5/4885PDE4A 2/4885PDE4C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.